Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Jesús G. Berdeja(Tennessee Oncology), Sundar Jagannath(Mount Sinai Hospital), Saad Z. Usmani(Memorial Sloan Kettering Cancer Center), Yunsi Olyslager(Janssen (Belgium)), Deepu Madduri(Johnson & Johnson (United States)), Enrique Zudaire(Centro de Investigación del Cáncer), A. Keith Stewart(Princess Margaret Hospital), Mounzer Agha(Dana-Farber Cancer Institute), Myo Htut(City Of Hope National Medical Center), Adam D. Cohen(Penn Center for AIDS Research), Parameswaran Hari(Medical College of Wisconsin), Alexander M. Lesokhin(Memorial Sloan Kettering Cancer Center), Syed Rizvi(Merck (Japan)), Nikhil C. Munshi(Dana-Farber Cancer Institute), Abhinav Deol(Wayne State University), David Avigan(Beth Israel Deaconess Medical Center), Marlene J. Carrasco-Alfonso, Elizabeth O’Donnell(Harvard University), Arnob Banerjee(Johnson & Johnson (United States)), Andrzej Jakubowiak(University of Chicago Medical Center), Farah Hossain, Thomas G. Martin(University of California San Francisco Medical Center), Frank Fan, Jordan M. Schecter(Centro de Investigación del Cáncer), William Deraedt(Janssen (Belgium)), Muhammad Akram(Unknown), Yi Lin, Xiaoling Wu(South China University of Technology), Tzu‐Min Yeh(Centro de Investigación del Cáncer), Indrajeet Singh(Janssen (United States)), Jeffrey R. Infante(Cancer Research Center), Sen Hong Zhuang(Janssen (United States)), Alicia J. Allred(Queen's University Belfast), Dong Geng, Carolyn C. Jackson(Centro de Investigación del Cáncer)

The Lancet

June 24, 2021

Cited by 1,705

|Nature|2013|10.1k

|New England Journal of Medicine|2013|6.6k

|New England Journal of Medicine|2013|4.2k

|Nature Medicine|2020|2.7k

|New England Journal of Medicine|2012|2.1k

Related Papers